A Phase I trial of protracted oral fixed-dose temozolomide

Cancer

Volumn 104, Issue 9, 2005, Pages 1985-1991

  Jones, Suzanne F ^a,b   Greco, F Anthony ^a,b   Gian, Victor G ^a,b   Miranda, Fernando T ^a,b   Raefsky, Eric L ^a,b   Hainsworth, John D ^a,b   Willcutt, Noel T ^a,b   Beschorner, Aurelia F ^a,b   Kennerly, Glyndon ^c   Burris III, Howard A ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Tennessee Oncology   (United States)

^c Workingknowledge LLC   (United States)

Author keywords

Dose limiting toxicity; Phase I; Protracted administration; Solid tumor types; Temozolomide

Indexed keywords

CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; FLUOROURACIL; IFOSFAMIDE; INTERFERON; INTERLEUKIN 2; MESNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 27244457264     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21408     Document Type: Article

References (14)

1. Temodar (temozolomide) capsules. Product package insert. Kenilworth, NJ: Schering Corporation, 2005.
2. Nagasubramanian R, Dolan ME. Temozolomide: realizing the promise and potential. Curr Opin Oncol. 2003;15:412-418.
3. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol. 2005;53:241-252.
4. Middleton MR, Grab JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
5. 6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 2001;7:2309-2317.
6. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6:2585-2597.
7. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;20:2388-2399.
8. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.
9. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367.
10. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs. 1992;10:239-253.
11. 6 alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest. 1985;76:2106-2114.
12. 6-benzylguanine plus BCNU. Blood. 1996;88:1649-1655.
13. Sharma P, Jazieh AR. Evaluation of the efficacy of prolonged administration of temozolomide as a salvage therapy for advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2003;22:705.
14. + lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22:610-616.